Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug
Open Access
- 18 July 2019
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 54 (1) , 56-63
Abstract
Objective: The purpose of this article is to review the literature for both 3,4-diaminopyridine (3,4-DAP) and amifampridine for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Amifampridine (Firdapse) is the salt form of 3,4-DAP and was approved by the Food and Drug Administration for the treatment of LEMS. Data Sources: PubMed, TRIP database, and EMBASE searches were conducted without a back date (current to June 2019) utilizing the following search terms: amifampridine, 3,4-diaminopyridine, and Lambert-Eaton myasthenic syndrome. Completed trials were also reviewed at clinicaltrials.gov. Study Selection and Data Extraction: Criteria for article inclusion consisted of human subjects, age ≥18 years, phase II or III clinical trials, and English language for both drugs. Observational and pharmacokinetic studies for amifampridine were also included. Data Synthesis: Prior to the approval of amifampridine, 3,4-DAP was first-line for the management of LEMS symptoms. Two phase III trials have evaluated amifampridine to confirm efficacy, both showing superiority over placebo in the management of LEMS symptoms, with minimal adverse effects. A significant improvement in both quantitative myasthenia gravis scores and Subjective Global Impression scores was established at days 4 and 14. Relevance to Patient Care and Clinical Practice: With an improved stability profile and decreased dose variability, amifampridine will likely assume the role of first-line management of LEMS. Conclusions: Amifampridine has been shown to improve symptoms of LEMS and is generally well tolerated.Keywords
This publication has 26 references indexed in Scilit:
- Elucidating the Molecular Basis of Action of a Classic Drug: Guanidine Compounds As Inhibitors of Voltage-Gated Potassium ChannelsMolecular Pharmacology, 2011
- Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategiesThe Lancet Neurology, 2011
- Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridineNeuropsychiatric Disease and Treatment, 2011
- The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2010
- 3,4‐Diaminopyridine is more effective than placebo in a randomized, double‐blind, cross‐over drug study in LEMSMuscle & Nerve, 2009
- Stability studies of ionised and non-ionised 3,4-diaminopyridine: Hypothesis of degradation pathways and chemical structure of degradation productsJournal of Pharmaceutical and Biomedical Analysis, 2007
- Available treatment options for the management of Lambert-Eaton myasthenic syndromeExpert Opinion on Pharmacotherapy, 2006
- Therapy in Myasthenia Gravis and Lambert-Eaton Myasthenic SyndromeSeminars in Neurology, 2003
- 3,4‐Diaminopyridine in Lambert‐Eaton Myasthenic Syndrome and Myasthenia GravisaAnnals of the New York Academy of Sciences, 1993
- 3,4-Diaminopyridine in the Treatment of Lambert–Eaton Myasthenic SyndromeNew England Journal of Medicine, 1989